Escitalopram Oxalate Market Size, Share and Trends Analysis Report, By Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and Generalized Anxiety Disorder), Forecast (2022-2028)

The escitalopram oxalate market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Escitalopram oxalates are commonly known as Lexapro and are used to treat depression, obsessive-compulsive disorder, and generalized anxiety disorder. Mood, sleep, appetite, and energy levels are all improved with this medicine. It is also been used to reduce fear, anxiety, unpleasant thoughts, and panic attacks. It lessens the desire to conduct repetitive chores that are inconvenient in everyday life. The rising prevalence of depression and anxiety are the major factors driving the growth of the global escitalopram oxalate market. According to the National Institute of Mental Health, in 2020, around 21.0 million adults in the US alone had at least one major depressive episode. This number represented 8.4% of all US adults. The prevalence of major depressive episodes was higher among adult females (10.5%) compared to males (6.2%). The prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (17.0%).

The global escitalopram oxalate market is segmented based on application. Based on application, the market is sub-segmented into MDD, OCD, and generalized anxiety disorder. Among these segments, the MDD segment is expected to propel the growth of the market due to the efficiency of these tablets in the treatment of MDD.

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers, acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2020. Lupin Pharmaceuticals, Inc. announced its recent product launch, Escitalopram Oxalate Tablets of power 5 mg, 10 mg, and 20 mg. Lupin’s Escitalopram Oxalate Tablets are the AB-rated generic equivalent of Forest’s Lexapro Tablets and are indicated for acute and maintenance treatment of MDD in adults and adolescents aged 12-17 years. It is also indicated for the acute treatment of generalized anxiety disorder in adults.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Pfizer Inc., Cipla Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?